LYMPHOCYTES AND LMYPHOKINES IN APLASTIC ANEMIA

临床研究的重点是发展更具体和更具体的 再生障碍性贫血患者的标准治疗。关于……的研究 环孢素已证明难治性肺炎患者 再生障碍性贫血可以通过这种形式的T- 细胞导向的免疫抑制。环孢素A导致 血液学应答率约为35%。增加了 强的松和维持适当的血液水平 环孢素似乎是该方案成功的重要因素。 再生障碍性贫血中造血生长因子的研究 从治疗三名重症患者开始， 包括严重的中性粒细胞减少症和频繁的细菌感染 使用重组人GM-CSF。在实验室研究中，单核细胞 来自再生障碍性贫血患者的已经被证明是非常差的 免疫的主要调节者白介素1(IL-1)的产生 也可能是造血细胞的增殖。Il.1 单核细胞培养中的活性与 再生障碍性贫血的成功治疗改善了中性粒细胞减少症 贫血。造血生长因子克服的能力 γ-射线对造血细胞增殖的负面影响 已经对干扰素进行了研究。粒细胞集落刺激因子对丙二醛无影响 干扰素抑制集落形成。GM-CSF可以克服 干扰素对骨髓细胞的负性作用及其IL-3的作用 对红细胞生成的影响，与其相对活性一致 这些因素对CFU-GM和BFU-E来源的集落形成有影响。

Clinical studies have focused the development of more specific and standard therapy for patients with aplastic anemia. A study of cyclosporine has demonstrated that patients with refractory aplastic anemia can improve hematologically with this form of T- cell directed immunosuppression. Cyclosporin A resulted in approximately 35% hematologic response rate. The addition of prednisone and the maintenance of adequate blood levels of cyclosporine appeared to be important for success of this regimen. Studies of hematopoietic growth factors in aplastic anemia have begun with the treatment of three patients with severe disease, including severe neutropenia and frequent bacterial infections using recombinant human GM-CSF. In laboratory studies, monocytes from patients with aplastic anemia have been shown to be very poor producers of interleukin 1 (Il-1), a principle regulator of immune and possibly also of hematopoietic cell proliferation. Il.1 activity in monocyte cultures was correlated to the degree of neutropenia and improved with successful therapy of aplastic anemia. The ability of hematopoietic growth factors to overcome the negative effects on hematopoietic cell proliferation of gamma interferon have been investigated. G-CSF had no effect on gamma interferon suppression of colony formation. GM-CSF could overcome gamma interferon's negative effect on myelopoiesis, and Il-3 its effect on erythropoiesis, consistent with the relative activity of these factors on CFU-GM and BFU-E- derived colony formation.